Supplementation with Selenium and Coenzyme Q10 reduces the risk of mortality from cardiovascular disease by 40 percent, for up to 12 years after their use, a Swedish study has found.
A follow-up on a study of 443 elderly healthy participants given dietary supplementation of 200 mg/day of Coenzyme Q10 capsules and 200 μg/day of organic Selenium yeast tablets or a similar placebo for 48 months, found that 12 years after the study, those that had been in the active treatment arm during the intervention had a significantly lower mortality.
“When evaluating the cardiovascular (CV) mortality within the 12-year period, we found that those on active treatment during the intervention had a significantly lower mortality also after 12 years.
“We observed a highly significant risk reduction resulting from supplementing the participants with Selenium and Coenzyme Q10 for four years, which was still present after 12 years,” the authors reported.
“The CV mortality risk reduction is significant and stable in all the well-known risk populations, including those with ischemic heart disease, hypertension or diabetes. It is striking that the reduction in CV mortality also remains after 12 years,” the authors stated.
The study also noted that even though the reduction in CV risk measured as reduced CV mortality is still significant, the effect seems somewhat less after 12 years than after ten years especially in the male group.
“This can probably be explained by the fact that ever-existing pathogenic factors catch up with the positive effects obtained by our intervention. Also, as reported previously, females have lower levels of Coenzyme Q10 than males, presumably explaining why the females benefited more than males from the supplementation.”
“The present 12-year evaluation of cardiovascular mortality after four years of intervention is unique and should be regarded as a validation of the surprising results from the 10-year evaluation and shows that the positive effects of the intervention persist.”
“The hypothesis arising from our results remains that the intervention with Selenium and Coenzyme Q10 inhibits the pathogenesis of irreversible, presumably structural, changes preceding cardiovascular events,” the authors said.
“The present follow-up study revealed a reduced cardiovascular mortality risk of more than 40%, in an elderly Swedish population that had been given supplementation with Selenium and Coenzyme Q10 for 48 months, 12 years earlier. A significant risk reduction, which was still seen in the subpopulations of the study that had hypertension, ischaemic heart disease, impaired cardiac function, and diabetes,” the authors concluded.
This Super Tuesday (October 2, 2018) we have both Selenium and CoQ10 on special. See our newsletter or come in store for details.